Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edesa Biotech (EDSA) Liabilities and Shareholders Equity (2016 - 2022)

Edesa Biotech's Liabilities and Shareholders Equity history spans 10 years, with the latest figure at $17.5 million for Q2 2022.

  • For Q2 2022, Liabilities and Shareholders Equity rose 3.93% year-over-year to $17.5 million; the TTM value through Sep 2022 reached $50.3 million, down 23.52%, while the annual FY2021 figure was $14.6 million, 35.52% up from the prior year.
  • Liabilities and Shareholders Equity for Q2 2022 was $17.5 million at Edesa Biotech, down from $20.4 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $24.0 million in Q1 2021 and bottomed at $3.4 million in Q4 2018.
  • The 5-year median for Liabilities and Shareholders Equity is $10.8 million (2020), against an average of $11.7 million.
  • The largest annual shift saw Liabilities and Shareholders Equity plummeted 48.46% in 2018 before it skyrocketed 214.46% in 2021.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $3.4 million in 2018, then surged by 49.76% to $5.1 million in 2019, then skyrocketed by 102.2% to $10.3 million in 2020, then grew by 19.95% to $12.3 million in 2021, then soared by 42.11% to $17.5 million in 2022.
  • Per Business Quant, the three most recent readings for EDSA's Liabilities and Shareholders Equity are $17.5 million (Q2 2022), $20.4 million (Q1 2022), and $12.3 million (Q4 2021).